BLLN (BillionToOne) Other Long-Term Liabilities: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLLN BillionToOne Inc BLLN
15 GF Score
Price $95.05
! 4 Warning Signs
View Full Analysis

What is BillionToOne Other Long-Term Liabilities?

BillionToOne BLLN -0.25% 15 Other Long-Term Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review.

BillionToOne's other long-term liabilities for the quarter that ended in Jun. 2026 was $0.0 Mil.

BillionToOne's quarterly other long-term liabilities declined from Dec. 2025 ($0.0 Mil) to Mar. 2026 ($0.0 Mil) but then stayed the same from Mar. 2026 ($0.0 Mil) to Jun. 2026 ($0.0 Mil).

BillionToOne's annual other long-term liabilities increased from Dec. 2023 ($251.3 Mil) to Dec. 2024 ($422.2 Mil) but then declined from Dec. 2024 ($422.2 Mil) to Dec. 2025 ($0.0 Mil).

BillionToOne Other Long-Term Liabilities Related Terms

BillionToOne Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for BillionToOne's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne Other Long-Term Liabilities Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
Other Long-Term Liabilities
251.33 422.17 0.00

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only 422.13 423.76 0.00 0.00 0.00
BLLN
15GF Score
BillionToOne Inc BLLN
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.0 Mil mean?
BillionToOne (BLLN) has a Other Long-Term Liabilities of $0.0 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on BillionToOne and its competitors.
Is BillionToOne's Other Long-Term Liabilities too high?
BillionToOne's current Other Long-Term Liabilities is $0.0 Mil. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Other Long-Term Liabilities compare to TWST and SHC?
BillionToOne's Other Long-Term Liabilities of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Other Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on BillionToOne and its competitors. BillionToOne's current Other Long-Term Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Other Long-Term Liabilities of $0.0 Mil. The current Other Long-Term Liabilities is $0.0 Mil. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For BillionToOne (BLLN), the current Other Long-Term Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score

Get the complete analysis for BLLN

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$95.05
Price